前收市價 | 0.2800 |
開市 | 0.2500 |
買盤 | 0.0000 |
賣出價 | 0.0000 |
拍板 | 40.50 |
到期日 | 2024-06-21 |
今日波幅 | 0.2400 - 0.5000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 1.51k |
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily.
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.